NewAmsterdam Pharma (NASDAQ:NAMS) Receives “Sell (D-)” Rating from Weiss Ratings

NewAmsterdam Pharma (NASDAQ:NAMS) Receives “Sell (D-)” Rating from Weiss Ratings